230. Alveolar hypoventilation syndrome Clinical trials / Disease details


Clinical trials : 8 Drugs : 11 - (DrugBank : 5) / Drug target genes : 18 - Drug target pathways : 28

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01500473
(ClinicalTrials.gov)
February 201222/12/2011Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation SyndromeTherapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation SyndromeCongenital Central Hypoventilation SyndromeDrug: DesogestrelChildren's Hospital Los AngelesNULLNot yet recruiting16 Years50 YearsFemale8N/AUnited States
2NCT01243697
(ClinicalTrials.gov)
April 201117/11/2010Assessment of Desogestrel in Ondine SyndromeAssessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine SyndromeOndine SyndromeDrug: desogestrelAssistance Publique - Hôpitaux de ParisNULLCompleted10 Years60 YearsFemale6Phase 2/Phase 3France
3EUCTR2011-000989-35-FR
(EUCTR)
06/05/2011N/AN/A - RESPIRONDINE
MedDRA version: 14.0;Level: PT;Classification code 10066131;Term: Congenital central hypoventilation syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Cerazette
Product Name: Cerazette
INN or Proposed INN: Désogestrel
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNAFemale: yes
Male: no
Phase 2France